Clearside Biomedical, Inc. Names Glenn Noronha, Ph.D., Executive Vice President, Research and Development

Clearside Biomedical, Inc. Names Glenn Noronha, Ph.D., Executive Vice President, Research and Development

ALPHARETTA, Ga.--(BUSINESS WIRE)--Clearside Biomedical, Inc., a privately held ophthalmic company developing and commercializing targeted therapeutics for the treatment of sight-threatening diseases, today announced Glenn Noronha, Ph.D., has been named to the position of Executive Vice President, Research and Development.

"He will add profound value to our R&D program and to the further development of our portfolio."
Noronha has 14 years of experience in the pharmaceutical industry where he served across clinical and nonclinical research and development, product development and other leadership roles. He has led multidisciplinary teams in many fields of medicine including ophthalmology, oncology and immunological and inflammatory diseases.

"Glenn has had extensive experience in planning and executing all stages of drug development that targets retinal diseases, including working with clinical, regulatory, scientific, non-clinical and technical areas for both small molecules and biologics," said Daniel White, Clearside's President and CEO. "He will add profound value to our R&D program and to the further development of our portfolio."

Most recently, Noronha was Vice President, Research and Development at Sucampo Pharma Americas, LLC. Prior to Sucampo, he was Chief Scientific Officer for JW Theriac, Inc., a pharmaceutical company focused on new drug research and development in the oncology therapeutic area. From 2008 through 2011, as Global Project Head, Noronha was responsible for execution of strategy in six ophthalmology projects across all stages of development in Alcon Laboratories' retina therapeutic area. Previously, Noronha held several positions of increasing responsibility at TargeGen, Inc., and Medtronic MiniMed, Inc.

Noronha received his Ph.D. from Loyola University, Chicago and conducted his post-doctoral research at the University of California, Irvine. He is a member of the Association for Research in Vision and Ophthalmology (ARVO) and is named on 21 pending or issued composition of matter and use patents for drugs in ophthalmology, oncology, immune and inflammatory diseases and in continuous glucose sensing. He is the author of more than 25 peer-reviewed articles and more than 50 scientific presentations at national and international forums.

About Clearside Biomedical, Inc.

Clearside Biomedical, Inc., headquartered in Alpharetta, Ga., is a clinical-stage ophthalmic pharmaceutical company that develops and commercializes targeted therapeutics to treat sight-threatening diseases. Clearside treats the pathological changes to the blood retinal barrier that lead to retinal blindness by delivering therapeutics through the suprachoroidal space to the retina and choroid using a proprietary microinjection dosage form. Clearside Biomedical was founded by an executive team with extensive development and revenue growth expertise. This team strives for better delivery and performance of its therapeutic agents to improve the standard of care for patients with retinal and choroidal disease. Visit www.clearsidebiomedical.com for more information.

Contacts

Clearside Biomedical, Inc.
Charles Deignan, 678-270-4005
[email protected]

Suggested Articles

The deal, which features an additional $2 billion in milestones, will give Bayer control of an AAV platform and a clinical-phase pipeline.

The result, which beats the 35% reported by KRAS rival Amgen, sets Mirati up to file for FDA approval of the drug in the second half of next year.

Scorpion is working on precision oncology 2.0, including making better drugs for known targets, hitting undruggable targets and discovering new ones.